I-Mab expands manufacturing for multiple myeloma antibody; Granules issued 'minor observations' after inspection

Josh Sullivan

China-based biopharma I-Mab has landed a partnership with Shanghai’s Hangzhou Qiantang New Area to manufacture drugs locally and speed up the company’s path toward commercialization …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

I-Mab expands manufacturing for multiple myeloma antibody; Granules issued 'minor observations' after inspection

Josh Sullivan

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

FDA approves subcutaneous version of Bristol Myers' Opdivo

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

I-Mab ex­pands man­u­fac­tur­ing for mul­ti­ple myelo­ma an­ti­body; Gran­ules is­sued 'mi­nor ob­ser­va­tion­s' af­ter in­spec­tion

Josh Sullivan

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

I-Mab expands manufacturing for multiple myeloma antibody; Granules issued 'minor observations' after inspection

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

FDA approves subcutaneous version of Bristol Myers' Opdivo

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma